Immunotherapy, PARP Inhibitors Picking Up Steam in TNBC Pipeline – OncLive
OncLive |
Immunotherapy, PARP Inhibitors Picking Up Steam in TNBC Pipeline
OncLive I also spoke a bit about the role of immunotherapy. This has been an area where we think that this type of cancer with unique molecular aberrations did not have great results with targeted therapies. Is this the place that immunotherapy agents might … |
